Transmembrane tumour necrosis factor is neuroprotective and regulates experimental autoimmune encephalomyelitis via neuronal nuclear factor-κB

Brain

Volumn 134, Issue 9, 2011, Pages 2722-2735

  Taoufik, Era ^a   Tseveleki, Vivian ^a   Chu, Seung Y ^b   Tselios, Theodore ^c   Karin, Michael ^d   Lassmann, Hans ^e   Szymkowski, David E ^b   Probert, Lesley ^a  

^a HELLENIC PASTEUR INSTITUTE   (Greece)

^b Xencor Inc   (United States)

^c UNIVERSITY OF PATRAS   (Greece)

^d San Diego   (United States)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

EAE; Multiple sclerosis; NF B; therapy; TNF

Indexed keywords

ETANERCEPT; GLUCOSE; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SOLUBLE TUMOR NECROSIS FACTOR; TRANSMEMBRANE TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR DERIVATIVE; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; XPRO 1595;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; ASTROCYTE; CENTRAL NERVOUS SYSTEM DISEASE; COCULTURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; IMMUNE RESPONSE; IMMUNOREACTIVITY; IN VITRO STUDY; INHIBITION KINETICS; MALE; MOUSE; MULTIPLE SCLEROSIS; NERVE CELL; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPINAL CORD LESION;

EID: 80052956995     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awr203     Document Type: Article

References (71)

1. Akassoglou K, Bauer J, Kassiotis G, Pasparakis M, Lassmann H, Kollias G, et al. Oligodendrocyte apoptosis and primary demyelination induced by local TNF/p55TNF receptor signaling in the central nervous system of transgenic mice: models for multiple sclerosis with primary oligo-dendrogliopathy. Am J Pathol 1998; 153: 801-13. (Pubitemid 28419033)
2. Akassoglou K, Douni E, Bauer J, Lassmann H, Kollias G, Probert L. Exclusive tumor necrosis factor (TNF) signaling by the p75TNF receptor triggers inflammatory ischemia in the CNS of transgenic mice. Proc Natl Acad Sci USA 2003; 100: 709-14. (Pubitemid 36126117)
3. Albensi BC, Mattson MP. Evidence for the involvement of TNF and NF-kappaB in hippocampal synaptic plasticity. Synapse 2000; 35: 151-9. (Pubitemid 30036192)
4. Alexopoulou L, Kranidioti K, Xanthoulea S, Denis M, Kotanidou A, Douni E, et al. Transmembrane TNF protects mutant mice against intracellular bacterial infections, chronic inflammation and autoimmun-ity. Eur J Immunol 2006; 36: 2768-80. (Pubitemid 44608460)
5. Aránguez I, Torres C, Rubio N. The receptor for tumor necrosis factor on murine astrocytes: characterization, intracellular degradation, and regulation by cytokines and Theiler's murine encephalomyelitis virus. Glia 1995; 13: 185-94.
6. Arnett HA, Mason J, Marino M, Suzuki K, Matsushima GK, Ting JP. TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci 2001; 4: 1116-22. (Pubitemid 34116557)
7. Baker D, Butler D, Scallon BJ, O'Neill JK, Turk JL, Feldmann M. Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur J Immunol 1994; 24: 2040-8.
8. Beattie EC, Stellwagen D, Morishita W, Bresnahan JC, Ha BK, Von Zastrow M, et al. Control of synaptic strength by glial TNFalpha. Science 2002; 295: 2282-5. (Pubitemid 34258846)
9. Berezovskaya O, Maysinger D, Fedoroff S. Colony stimulating factor-1 potentiates neuronal survival in cerebral cortex ischemic lesion. Acta Neuropathol 1996; 92: 479-86. (Pubitemid 26356539)
10. Botchkina GI, Meistrell ME, Botchkina IL, Tracey KJ. Expression of TNF and TNF receptors (p55 and p75) in the rat brain after focal cerebral ischemia. Mol Med 1997; 3: 765-81. (Pubitemid 28047420)
11. Brambilla R, Ashbaugh JJ, Magliozzi R, Dellarole A, Karmally S, Szymkowski DE, et al. Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination. Brain 2011; 134: 2736-54.
12. Breder CD, Tsujimoto M, Terano Y, Scott DW, Saper CB. Distribution and characterization of tumor necrosis factor-alpha-like immunoreactivity in the murine central nervous system. J Comp Neurol 1993; 337: 543-67. (Pubitemid 23323643)
13. Camandola S, Mattson MP. NF-kappa B as a therapeutic target in neurodegenerative diseases. Expert Opin Ther Targets 2007; 11: 123-32. (Pubitemid 46188809)
14. Centonze D, Muzio L, Rossi S, Cavasinni F, De Chiara V, Bergami A, et al. Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. J Neurosci 2009; 29: 3442-52.
15. Chen JW, Breckwoldt MO, Aikawa E, Chiang G, Weissleder R. Myeloperoxidase-targeted imaging of active inflammatory lesions in murine experimental autoimmune encephalomyelitis. Brain 2008; 131: 1123-33. (Pubitemid 351499418)
16. De Jager PL, Jia X, Wang J, de Bakker PI, Ottoboni L, Aggarwal NT, et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 2009; 41: 776-82.
17. Emmanouil M, Taoufik E, Tseveleki V, Vamvakas SS, Tselios T, Karin M, et al. Neuronal I kappa B kinase beta protects mice from autoimmune encephalomyelitis by mediating neuroprotective and immunosuppres-sive effects in the central nervous system. J Immunol 2009; 183: 7877-89.
18. Eugster HP, Frei K, Bachmann R, Bluethmann H, Lassmann H, Fontana A. Severity of symptoms and demyelination in MOG-induced EAE depends on TNFR1. Eur J Immunol 1999; 29: 626-32. (Pubitemid 29078524)
19. Eugster HP, Frei K, Kopf M, Lassmann H, Fontana A. IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune en-cephalomyelitis. Eur J Immunol 1998; 28: 2178-87. (Pubitemid 28321302)
20. Filipovic R, Jakovcevski I, Zecevic N. GRO-alpha and CXCR2 in the human fetal brain and multiple sclerosis lesions. Dev Neurosci 2003; 25: 279-90. (Pubitemid 37100220)
21. Frei K, Eugster HP, Bopst M, Constantinescu CS, Lavi E, Fontana A. Tumor necrosis factor alpha and lymphotoxin alpha are not required for induction of acute experimental autoimmune encephalomyelitis. J Exp Med 1997; 185: 2177-82. (Pubitemid 27266001)
22. Fremond C, Allie N, Dambuza I, Grivennikov SI, Yeremeev V, Quesniaux VF, et al. Membrane TNF confers protection to acute mycobacterial infection. Respir Res 2005; 6: 136.
23. Gary DS, Bruce-Keller AJ, Kindy MS, Mattson MP. Ischemic and excito-toxic brain injury is enhanced in mice lacking the p55 tumor necrosis factor receptor. J Cereb Blood Flow Metab 1998; 18: 1283-7. (Pubitemid 28559674)
24. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002; 109 (Suppl): S81-96.
25. Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006; 129: 1953-71. (Pubitemid 44289062)
26. Gray E, Thomas TL, Betmouni S, Scolding N, Love S. Elevated activity and microglial expression of myeloperoxidase in demyelinated cerebral cortex in multiple sclerosis. Brain Pathol 2008; 18: 86-95.
27. Grell M, Douni E, Wajant H, Löhden M, Clauss M, Maxeiner B, et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995; 83: 793-802.
28. Kassiotis G, Kollias G. Uncoupling the proinflammatory from the im-munosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J Exp Med 2001; 193: 427-34. (Pubitemid 32524474)
29. Korner H, Riminton DS, Strickland DH, Lemckert FA, Pollard JD, Sedgwick JD. Critical points of tumor necrosis factor action in central nervous system autoimmune inflammation defined by gene targeting. J Exp Med 1997; 186: 1585-90. (Pubitemid 27479818)
30. Kreuz S, Siegmund D, Scheurich P, Wajant H. NF-kappaB inducers upre-gulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol Cell Biol 2001; 21: 3964-73. (Pubitemid 32476458)
31. Krishnamoorthy G, Lassmann H, Wekerle H, Holz A. Spontaneous opti-cospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation. J Clin Invest 2006; 116: 2385-92. (Pubitemid 44330137)
32. Lambertsen KL, Clausen BH, Babcock AA, Gregersen R, Fenger C, Nielsen HH, et al. Microglia protect neurons against ischemia by synthesis of tumor necrosis factor. J Neurosci 2009; 29: 1319-30.
33. Lassmann H. Hypoxia-like tissue injury as a component of multiple sclerosis lesions. J Neurol Sci 2003; 206: 187-91. (Pubitemid 36143726)
34. Lewis M, Tartaglia LA, Lee A, Bennett GL, Rice GC, Wong GH, et al. Cloning and expression of cDNAs for two distinct murine tumor. Proc Natl Acad Sci USA 1991; 88: 2830-4.
35. Li ZW, Omori SA, Labuda T, Karin M, Rickert RC. IKK beta is required for peripheral B cell survival and proliferation. J Immunol 2003; 170: 4630-7. (Pubitemid 36519969)
36. Liu J, Marino MW, Wong G, Grail D, Dunn A, Bettadapura J, et al. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated de-myelination. Nat Med 1998; 4: 78-83. (Pubitemid 28133083)
37. Mahad DJ, Ransohoff RM. The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Semin Immunol 2003; 15: 23-32. (Pubitemid 36092176)
38. Marchetti L, Klein M, Schlett K, Pfizenmaier K, Eisel UL. Tumor necrosis factor (TNF)-mediated neuroprotection against glutamate-induced excitotoxicity is enhanced by N-methyl-D-aspartate receptor activation. Essential role of a TNF receptor 2-mediated phosphatidylinositol 3-kinase-dependent NF-kappa B pathway. J Biol Chem 2004; 279: 32869-81. (Pubitemid 39014747)
39. McCoy MK, Martinez TN, Ruhn KA, Szymkowski DE, Smith CG, Botterman BR, et al. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J Neurosci 2006; 26: 9365-75. (Pubitemid 44396849)
40. Minichiello L, Korte M, Wolfer D, Kuhn R, Unsicker K, Cestari V, et al. Essential role for TrkB receptors in hippocampus-mediated learning. Neuron 1999; 24: 401-14. (Pubitemid 29508413)
41. Miyagishi R, Kikuchi S, Takayama C, Inoue Y, Tashiro K. Identification of cell types producing RANTES, MIP-1 alpha and MIP-1 beta in rat experimental autoimmune encephalomyelitis by in situ hybridization. J Neuroimmunol 1997; 77: 17-26. (Pubitemid 27286372)
42. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001; 44: 2862-9. (Pubitemid 34016206)
43. Murray KM, Dahl SL. Recombinant human tumor necrosis factor receptor (p75) Fc fusion protein (TNFR:Fc) in rheumatoid arthritis. Ann Pharmacother 1997; 31: 1335-8. (Pubitemid 27498022)
44. Nicole O, Ali C, Docagne F, Plawinski L, MacKenzie ET, Vivien D, et al. Neuroprotection mediated by glial cell line-derived neurotrophic factor: involvement of a reduction of NMDA-induced calcium influx by the mitogen-activated protein kinase pathway. J Neurosci 2001; 21: 3024-33. (Pubitemid 32323484)
45. Nomura T, Abe Y, Kamada H, Shibata H, Kayamuro H, Inoue M, et al. Therapeutic effect of PEGylated TNFR1-selective antagonistic mutant TNF in experimental autoimmune encephalomyelitis mice. J Control Release 2011; 149: 8-14.
46. Oikonomou N, Harokopos V, Zalevsky J, Valavanis C, Kotanidou A, Szymkowski DE, et al. Soluble TNF mediates the transition from pulmonary inflammation to fibrosis. PLoSOne 2006; 1: e108.
47. Olleros ML, Vesin D, Fotio AL, Santiago-Raber ML, Tauzin S, Szymkowski DE, et al. Soluble TNF, but not membrane TNF, is critical in LPS-induced hepatitis. J Hepatol 2010; 53: 1059-68.
48. Olleros ML, Vesin D, Lambou AF, Janssens JP, Ryffel B, Rose S, et al. Dominant-negative tumor necrosis factor protects from Mycobacterium bovis Bacillus Calmette Guerin (BCG) and endotoxin-induced liver injury without compromising host immunity to BCG and Mycobacterium tuberculosis. J Infect Dis 2009; 199: 1053-63.
49. Omari KM, John G, Lango R, Raine CS. Role for CXCR2 and CXCL1 on glia in multiple sclerosis. Glia 2006; 53: 24-31. (Pubitemid 43076209)
50. Park JM, Greten FR, Li ZW, Karin M. Macrophage apoptosis by anthrax lethal factor through p38 MAP kinase inhibition. Science 2002; 297: 2048-51.
51. Ransohoff RM, Hamilton TA, Tani M, Stoler MH, Shick HE, Major JA, et al. Astrocyte expression of mRNA encoding cytokines IP-10 and JE/MCP-1 in experimental autoimmune encephalomyelitis. FASEB J 1993; 7: 592-600. (Pubitemid 23120908)
52. Ruddle NH, Bergman CM, McGrath KM, Lingenheld EG, Grunnet ML, Padula SJ, et al. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med 1990; 172: 1193-200. (Pubitemid 20343220)
53. Ruuls SR, Hoek RM, Ngo VN, McNeil T, Lucian LA, Janatpour MJ, et al. Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation. Immunity 2001; 15: 533-43. (Pubitemid 33016439)
54. Santello M, Bezzi P, Volterra A. TNFalpha controls glutamatergic glio-transmission in the hippocampal dentate gyrus. Neuron 2011; 69: 988-1001.
55. Saunders BM, Tran S, Ruuls S, Sedgwick JD, Briscoe H, Britton WJ. Transmembrane TNF is sufficient to initiate cell migration and granu-loma formation and provide acute, but not long-term, control of Mycobacterium tuberculosis infection. J Immunol 2005; 174: 4852-9.
56. Schmidt D, Textor B, Pein OT, Licht AH, Andrecht S, Sator-Schmitt M, et al. Critical role for NF-kappaB-induced JunB in VEGF regulation and tumor angiogenesis. EMBO J 2007; 26: 710-19.
57. Selmaj K, Raine CS, Cross AH. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann Neurol 1991; 30: 694-700.
58. Shohami E, Ginis I, Hallenbeck JM. Dual role of tumor necrosis factor alpha in brain injury. Cytokine Growth Factor Rev 1999; 10: 119-30. (Pubitemid 29446376)
59. Simi A, Tsakiri N, Wang P, Rothwell NJ. Interleukin-1 and inflammatory neurodegeneration. Biochem Soc Trans 2007; 35: 1122-6. (Pubitemid 350206443)
60. Steed PM, Tansey MG, Zalevsky J, Zhukovsky EA, Desjarlais JR, Szymkowski DE, et al. Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science 2003; 301: 1895-8. (Pubitemid 37221393)
61. Steinman L, Zamvil SS. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends Immunol 2005; 26: 565-71. (Pubitemid 41726443)
62. Stellwagen D, Beattie EC, Seo JY, Malenka RC. Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha. J Neurosci 2005; 25: 3219-28. (Pubitemid 40463557)
63. Stubgen JP. Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve 2008; 37: 281-92.
64. Taoufik E, Valable S, Müller GJ, Roberts ML, Divoux D, Tinel A, et al. FLIP(L) protects neurons against in vivo ischemia and in vitro glucose deprivation-induced cell death. J Neurosci 2007; 27: 6633-46. (Pubitemid 46983433)
65. Taylor PC, Feldmann M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol 2009; 5: 578-82.
66. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999; 53: 457-65.
67. Thompson WL, Van Eldik LJ. Inflammatory cytokines stimulate the che-mokines CCL2/MCP-1 and CCL7/MCP-3 through NFkB and MAPK dependent pathways in rat astrocytes. Brain Res 2009; 1287: 47-57.
68. Torres D, Janot L, Quesniaux VF, Grivennikov SI, Maillet I, Sedgwick JD, et al. Membrane tumor necrosis factor confers partial protection to Listeria infection. Am J Pathol 2005; 167: 1677-87. (Pubitemid 41713319)
69. van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, von Blomberg BM, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996; 47: 1531-4. (Pubitemid 26422549)
70. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003; 10: 45-65. (Pubitemid 36511832)
71. Zalevsky J, Secher T, Ezhevsky SA, Janot L, Steed PM, O'Brien C, et al. Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. J Immunol 2007; 179: 1872-83.